Longer term holders than me (early 2019) may be able to enlighten me whatever became of the 2016 proposal to cross list on NASDAQ.
Obviously, getting human/canine trials running will cost big bucks. A further 10% dilution doesn't sit well with most holders.
Does anyone else think that re-visiting a NASDAQ listing could be a potential solution to funding trials now that the Elanco option is defunct?
I don't know the circumstances surrounding the 2016 attempt. Surely we are in a stronger position now. An IPO could raise sufficient capital to progress our trials as well as broaden our reputation.
Happy to hear any thoughts...
Good luck to all holders, Thrifty
- Forums
- ASX - By Stock
- PAA
- PharmAust - Now that is impressive
PharmAust - Now that is impressive, page-108
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M |
Open | High | Low | Value | Volume |
19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 135256 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 79851 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 135256 | 0.200 |
9 | 87953 | 0.195 |
13 | 840004 | 0.190 |
12 | 226560 | 0.185 |
18 | 352803 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 79851 | 3 |
0.210 | 269460 | 5 |
0.215 | 103895 | 2 |
0.220 | 506039 | 7 |
0.225 | 420666 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |